KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Operations (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Cash from Operations for 6 consecutive years, with 34743000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 334.29% year-over-year to 34743000.0, compared with a TTM value of 131295000.0 through Dec 2025, down 20.95%, and an annual FY2025 reading of 131295000.0, down 20.95% over the prior year.
  • Cash from Operations was 34743000.0 for Q4 2025 at AbCellera Biologics, up from 52594000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 273015000.0 in Q2 2022 and bottomed at 126786000.0 in Q3 2022.
  • Average Cash from Operations over 5 years is 11910800.0, with a median of 14133000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations skyrocketed 14438.35% in 2021, then tumbled 27147.17% in 2024.
  • Year by year, Cash from Operations stood at 16712000.0 in 2021, then skyrocketed by 284.97% to 30912000.0 in 2022, then crashed by 163.44% to 19611000.0 in 2023, then surged by 59.21% to 8000000.0 in 2024, then crashed by 334.29% to 34743000.0 in 2025.
  • Business Quant data shows Cash from Operations for ABCL at 34743000.0 in Q4 2025, 52594000.0 in Q3 2025, and 32404000.0 in Q2 2025.